October 30, 2023 07:28 AM EDTUpdated 09:02 AM

FDA greenlights first made-in-China PD-1 as Junshi, Coherus beat BeiGene to the punch

Amber Tong

The first Chinese PD-1 is coming to the US market, as the FDA approves toripalimab in recurrent or metastatic nasopharyngeal carcinoma (NPC) across all lines …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA greenlights first made-in-China PD-1 as Junshi, Coherus beat BeiGene to the punch

Amber Tong

Sign up to read this article for free.

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

GSK makes case for Blenrep's return with new blood cancer survival data

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?

FDA green­lights first made-in-Chi­na PD-1 as Jun­shi, Co­herus beat BeiGene to the punch

Amber Tong

Sign up to read this article for free.

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

FDA greenlights first made-in-China PD-1 as Junshi, Coherus beat BeiGene to the punch

Merck buys into PD-1/VEGF space as Summit comes for Keytruda

Exclusive: Ascidian CEO Michael Ehlers leaves Apple Tree Partners for MPM BioImpact

FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe

Metsera raises $215M for studies of GLP-1 and amylin obesity drugs

GSK makes case for Blenrep's return with new blood cancer survival data

What Will It Take to Reverse Fibrosis in Patients with Advanced MASH?